Xgeva: risk of hypocalcaemia in cancer setting

Amgen has sent a letter to healthcare professionals reminding them of the risk of severe symptomatic hypocalcaemia associated with use of Xgeva (denosumab) and highlighting the potential for late-onset hypocalcaemia.

Xgeva is given by subcutaneous injection every four weeks

Xgeva is indicated for the prevention of skeletal events (including pathological fracture, radiation or surgery to bone, and spinal cord compression) in patients with bone metastases caused by solid tumours. Hypocalcaemia was identified as a common adverse event in clinical trials; however, severe fatal cases have been reported in the postmarketing period.

Higher risk when initiating therapy

Hypocalcaemia can occur at any time during therapy with denosumab but most commonly occurs within the first six months of dosing. In severe cases, the patient may present with altered mental status, tetany, seizures and QT interval prolongation. 

Prescribers are reminded of the following recommendations to minimise risk:

  • Correct hypocalcaemia before starting therapy
  • Administer calcium and vitamin D supplements unless hypercalcaemia is present
  • Consider additional calcium supplementation if hypocalcaemia occurs
  • Monitor calcium levels in patients with severe renal impairment (CrCl <30ml/min) or receiving dialysis.

View Xgeva drug record

View letter to healthcare professionals

Further information: Amgen

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...